- Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target Conference
- Updated data from the TTI-621 intralesional trial in patients with mycosis fungoides and Sézary Syndrome at the EORTC CLTF 2018 Meeting
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. TRIL TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's TTI-621 clinical programs at two upcoming scientific conferences.
16th Annual Discovery on Target - Targeting Tumor Myeloid Cells:
| Title: Presenter: Date and Time: Location: | Blocking the CD47 "Do Not Eat" Signal with SIRPaFc Fusion Proteins Dr. Robert Uger, Chief Scientific Officer Sept. 28, 2018, 10:45 a.m. ET Sheraton Boston, Boston, MA |
EORTC CLTF 2018 Meeting Cutaneous Lymphoma:
| Title: | Intralesional Injection of the CD47-blocking Immune Checkpoint Inhibitor TTI-621 (SIRPaFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase 1 Trial |
| Presenter: | Dr. Christiane Querfeld, City of Hope Cancer Center & Beckman Research Institute |
| Presentation number: | 093 |
| Session: | Oral presentation, Session 7 / Treatment and clinical aspects |
| Date and Time: | Sept. 28, 2018, 5:10 p.m. – 6:10 p.m. CEST |
| Location: | Olma Messen Hall 9.2, St. Gallen, Switzerland |
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets. For more information, please visit www.trilliumtherapeutics.com
Contact:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
Investor and Media Relations:
Jessica Tieszen
Canale Communications for Trillium Therapeutics
619-849-5385
jessica@canalecomm.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
